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Abstract
Background: The clinical outcomes of short interruptions of PI-based ART regimens remains undefined.
Methods: A 2-arm non-inferiority trial was conducted on 53 HIV-1 infected South African participants with viral load ,50
copies/ml and CD4 T cell count .450 cells/ml on stavudine (or zidovudine), lamivudine and lopinavir/ritonavir. Subjects were
randomized to a) sequential 2, 4 and 8-week ART interruptions or b) continuous ART (cART). Primary analysis was based on
the proportion of CD4 count .350 cells(c)/ml over 72 weeks. Adherence, HIV-1 drug resistance, and CD4 count rise over
time were analyzed as secondary endpoints.
Results: The proportions of CD4 counts .350 cells/ml were 82.12% for the intermittent arm and 93.73 for the cART arm; the
difference of 11.95% was above the defined 10% threshold for non-inferiority (upper limit of 97.5% CI, 24.1%; 2-sided CI:
20.16, 23.1). No clinically significant differences in opportunistic infections, adverse events, adherence or viral resistance
were noted; after randomization, long-term CD4 rise was observed only in the cART arm.
Conclusion: We are unable to conclude that short PI-based ART interruptions are non-inferior to cART in retention of
immune reconstitution; however, short interruptions did not lead to a greater rate of resistance mutations or adverse events
than cART suggesting that this regimen may be more forgiving than NNRTIs if interruptions in therapy occur.
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Introduction
Antiretroviral Therapy (ART) is available in resource-con-
strained countries through governmental and international
funding programs, which have begun to impact the survival of
communities [1]. Several studies suggest that adherence to ART in
sub-Saharan Africa is adequate [2], but may be disrupted by
supply chain interruptions, stock outs, power outages affecting
medication storage, employment migration, conflict, and signifi-
cant cultural stigma [3,4,5]. For example, rates of therapy
interruptions in regular therapy management in Sub-Saharan
Africa have been reported at 12.8 per 100 person years [6].
Prior studies of CD4-guided ART interruptions in patients with
low CD4 counts have not been promising: the largest study to date
(SMART) showed that a strategy of structured treatment
interruptions (STI) guided by CD4
+ T cell count (average time
off therapy of 16.8 months) was associated with significant non-
HIV related morbidities [7,8]. The duration of uncontrolled HIV
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21450viral replication was associated with higher risk of opportunistic
infections (OI) [9]. A second study evaluating structured
interruptions in Corte d’Ivoire (TRIVACAN study [10]) assessed
three scheduled interruptions of 2 months each followed by 4
months of continuous ART (c-ART) compared with continuous
NNRTI-based ART in subjects with a median pre-ART CD4
+ T
cell count nadir of 272 cells/ml. While the interruption arm was
considered to be non-inferior, there was a significantly higher rate
of resistance to non-nucleotides (NNRTIs) in the experimental
arm. Importantly, both SMART and TRIVACAN had low re-
treatment thresholds (CD4
+ T cell count ,250 cells/ml), exposing
subjects to prolonged periods of immunodeficiency. Results from
the CD4-driven STACCATO study [11], with re-treatment
threshold of CD4
+ T cell count ,350 cells/ml, suggest that higher
CD4
+ thresholds may minimize the risks of interrupting ART,
although even in that study the interrupting ARM had higher
frequency of candidiasis.
While open-ended CD4-driven treatment interruptions result in
worse outcomes for subjects interrupting ART, trials incorporating
fixed-length shorter treatment interruptions have yielded mixed
results: the DART study used pre-determined cyclic 12 week ART
interruption arms and found this strategy to be inferior due to a
higher rate of disease progression than in continuous therapy.
However, this study included patients with low CD4
+ T cell count
nadirs (86 cells/ml) and 52% of DART participants had a previous
episode of oral or oesophageal candidiasis [12]. The ISS-PART
study, conducted in Italy with ART interruptions increasing in
length from 1 to 3 months, did not result in virological failures
even though resistance mutations and lower frequency of CD4
+ T
cell count .500 cells/ml were noted in interrupting subjects [13].
The France-based ANSR-106 study [14], which used a 2-month
on/2-month off treatment strategy, did not result in clinical
endpoint differences between arms (CD4
+ T cell count .300
cells/ml), but the interrupting arm had higher frequency of
lymphadenitis and candidiasis. The ACTG-5068 study [15]
incorporated 2 ART interruptions of 4 and 8 weeks. In this study,
subjects on the interrupting arm were able to maintain a viral load
,1000 copies/ml at greater frequency that subjects on the
continuous ART arm, indicating a possible advantage for
intermittent treatment strategies. Time to rebound to VL.5000
copies/ml upon ART cessation were similar between interrupting
and continuous treatment arm in our Philadelphia-based study
[16], which also found no significantly different clinical outcomes.
Together, the current literature (reviewed in [17,18]) suggest that
long (e.g. mean 16.8 months in SMART), open ended ART
interruption carry an immunological penalty for individuals on
NNRTI-based regimens, even when relatively high CD4
+ T cell
count safety thresholds are in place. However, the immunological
and clinicalconsequences of brief(up to 8 weeks)ARTinterruptions
in individuals with higher CD4
+ T cell count on a PI-based regimen
has not been determined, and the present study was initiated with
the intent of assessing the immunologic and virologic changes
occurring as a consequence of such interruptions.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
The study was conducted at the Themba Lethu HIV care and
treatment clinic located in a secondary government hospital in
Johannesburg South Africa.
Written informed consent was obtained from all study subjects;
consent procedure included two educational sessions with
confirmed understanding by the site investigator. Study protocol
and consent form/procedures were approved by the University of
Witwatersrand Ethics Committee and the IRB at Wistar Institute.
Objectives
To test the hypothesis that intermittent short cyclic treatment
interruptions would be non-inferior to continuous therapy in
maintaining ART-mediated immune reconstitution, we conducted
an open labelled randomized controlled study of short ART
interruption in patients with CD4
+ T cell count .450 on therapy
as compared with continuous treatment.
Study participants
Eligible participants were $18 years of age, ART naı ¨ve with
CD4
+ T cell count between 200–350 cells/ml, no history of
opportunistic infection, and laboratory values#grade 2 (per the
DAIDS toxicity table August 2004 [19]). Patients had to be off all
immunomodulatory therapy 4 weeks before enrolling and
thorough out the study. Pregnant and breast feeding women and
those with hepatitis B or C infection were not eligible.
Study procedures
Patients were started on weight based stavudine, lamuvidine
and lopinavir/ritonovir regimens and were allowed to switch to
zidovudine for stavudine toxicity. Other ART switches were not
Table 1. Outcome attribution rules.
Event Outcome Arm 1 (n) Arm 2 (n)
SAE Impute failure from date of occurrence 2 2
AIDS-defining illness Impute failure from date of occurrence 1 0
Lack of resuppression* Impute failure from date of occurrence 3 0
Pregnancy Censor from occurrence 0 1
Withdrawal of IC Censor from occurrence 0 0
LTFU Censor from occurrence 0 1
CD4 failure Fail visit 22 5
Missing data Censor visit 8 4
*After 12 weeks on previous ART regimen. All patients achieved VL,50 copies/ml without ART regimen changes as described in results section.
doi:10.1371/journal.pone.0021450.t001
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another ART regimen was needed.
Participants were randomized to either the short term
structured interruption arm (Arm 1) or continuous therapy arm
(Arm 2) at study week 24 if the HIV viral load was confirmed to be
,50 copies/ml and the CD4
+ T cell count was $450 cells/ml.
Other criteria necessary for randomization were laboratory
values#grade 2 [19], the absence of an active AIDS –defining
diagnosis, opportunistic infection or a condition requiring acute
therapy.
Figure 1. Subject disposition chart. Information regarding subject disposition during the trial is presented according to CONSORT guidelines
(http://www.consort-statement.org). Abbreviations used in this table: LTFU: lost to follow-up; O.I.: opportunistic infection; T.I.A.: transient ischemic
attacks.
doi:10.1371/journal.pone.0021450.g001
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or continued therapy using permuted block randomization with
random block sizes of 6 to 9, to maintain an equal number of
subjects in each group, according to a list generated by the study
statistician. A sufficient number of individual envelopes, sealed and
sequentially numbered, containing the arm assignment for each
subject, were provided by the study statistician, and opened in the
same order by an independent individual with no patient contact
(site Data Manager) at the time of randomization. Specific site
training was provided to ensure the correctness of the procedure.
Participants who were randomized to arm 1 were followed
every 4 to 12 weeks for 72 weeks. Three sequential interruption of
treatment of 2, 4 and 8 weeks took place with 16 weeks of therapy
in between each interruption, a strategy that had proven safe for
participants in our prior study [16]. Interruption of ART did not
occur if CD4
+ T cell count was ,400 cells/ml, viral load .5,000
copies /ml or if failure to demonstrate a viral load decline of .1
log copies/ml at 12 weeks after a previous interruption. If any of
these occurred, the patient continued ART and HIV viral load
and CD4
+ T cell count were rechecked in one month. If the above
criteria were not met at 16 weeks after ART, the patient was
declared to have reached the primary endpoint and discontinued
from the experimental procedure yet continually monitored for
suppression. Patients in arm 2 were followed every 8 weeks for 72
weeks after randomization. For both arms, HIV viral load,
complete blood count, CD4
+ T cell count, liver function tests,
electrolytes and blood samples were collected at each study visit.
Adherence was assessed via pill count and patient self-report. If the
HIV viral load was .5,000 copies/ml on ART, treatment
adherence counselling was implemented and genotypic resistance
testing was performed. If the HIV viral load remained .5,000
copies/ml for an additional 16 weeks the subject was declared to
have reached primary endpoint.
Genotypic Resistance Testing. Viral RNA was extracted
from plasma using the QIAamp Viral RNA Mini kit (QIAGEN
Group, Germany). RNA extractions were incubated at 37uC for
2 hours with 1–5 U Heparinase (Sigma Aldrich) and 40 U RNase
Inhibitor in a 10 mM Tris pH 7.5, 1 mM CaCl
2 solution, to a
total volume of 140 ml, and then re-extracted to remove the
enzymes. Sequencing of the pol gene was done using an in-house
assay [20] and BigDye Terminators v3.1 on an ABI3100 Genetic
Analyzer (Applied Biosystems, Foster City, CA). Consensus
sequences were aligned and manually edited using the
Sequencher v4.5 software (GeneCodes, Ann Arbor, MI).
Genotypic resistance was defined using the Stanford Genotypic
Resistance Interpretation Algorithm (http://hivdb.stanford.edu/)
and the December 2009 International AIDS Society drug
resistance mutation list.
Primary and Secondary Outcomes
The primary outcome was the proportion of CD4
+ T cell count
measurements .350 cells/ml (‘‘success’’) over 72 weeks of follow-
up following randomization (i.e. 10 measurements for cART
Figure 2. Visit viral load count outcomes. Stacked bars and numbers represent the number of subjects with HIV RNA,50 copies/ml
(suppressed, closed bars) and $50 copies/ml (viremic, open bars) at each post-randomization visit are reported for the control continuous treatment
arm (top panels, cART) and the ART-interrupting arm (bottom panel, interrupting). The treatment line below the graphics represent the time on and
off ART for each study.
doi:10.1371/journal.pone.0021450.g002
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points for measuring CD4
+ T cell count occurred during and after
3 cyclic interruptions of 2, 4 and 8 weeks in arm 1 and every two
months in arm 2. For individuals deemed to have reached the
primary endpoint (e.g., opportunistic infection), CD4
+ T cell count
results at all subsequent time points were imputed to be ,350
cells/ml. Secondary outcomes of the study included treatment-
associated toxicity, adherence and CD4
+ T cell count change over
time.
Monitoring and Interim Analyses: interim safety monitoring
reports on CD4
+ T cell count, HIV viral loads and clinical HIV
disease progression and other adverse events were reviewed by the
NIH/NIAID DAIDS Therapeutic Data and Safety Monitoring
Boards.
Statistical analysis
Primary analysis. A one sided 97.5% confidence intervals
for the difference (continuous-experimental) in mean proportion of
CD4
+ T cell count .350 cells/ml over 72 weeks post
randomization between the two study arms was constructed.
Non-inferiority was concluded if the right-hand limit of the
confidence interval was ,10%. A sample size of 52 individuals was
targeted to achieve 85% power for detecting non-inferiority based
on a two-group, one-sided level 0.025 t-test with an expected
difference of 4 between the two arms. For individuals reaching the
primary endpoint (e.g., opportunistic infection) prior to 72 weeks
after randomization, CD4
+ T cell count at all subsequent time
points were treated as ,350 cells//ml (‘‘imputed’’), as described in
Table 1.
Secondary analyses. Adherence over the post-rand-
omization period was defined as 1 minus the difference between
the actual and expected pill counts returned, adjusted for dose
(number of pills per day) and number of days since drug
dispensation. Two-sided, level=0.05 Wilcoxon rank sum tests
were applied to test the null hypothesis of no difference in
adherence between the two study arms.
The long-term effect of intermittent ART on the retention of
the CD4 recovery benefits derived from 6 months of continuous
viral suppression was also considered. Here a mixed effects model
was fitted to all on-ART CD4
+ T cell count measurements with
person specific random effects, as well as fixed effects for baseline
(pre-randomization) CD4
+ T cell count, study week, randomiza-
tion arm and an interaction between study week and randomi-
zation arm. Finally, we fitted a series of linear models to determine
whether CD4
+ T cell count or viral load pre-ART were predictive
of CD4
+ T cell count or viral load, respectively, at end of each
interruption. For modelling approaches, Wald tests were used to
test whether the fixed effects coefficients were equal to 0 and
resultant p-values of less than 0.05 were considered statistically
significant.
Results
Participants’ clinical and demographic characteristics
Between July 2005 and July 2009, 116 participants were initially
enrolled into the study and initiated ART (stavudine, lamivudine
and lopinavir/ritonavir). There was one death pre-randomization
due to sepsis and lactic acidosis. 53 subjects were randomized to
intermittent treatment (arm 1, n=27) or continuous treatment
(arm 2, n=26). Subject disposition is summarized in Fig. 1.
The study consisted of 69% women with a mean age of 35 years
(SD=8 years). The mean baseline CD4
+ T cell count was 270
cells/ml (SD=60) and log10 HIV log10 viral load was 4.6
(SD=0.64) upon enrolment; at randomization after an average
of 24 weeks on c-ART CD4
+ T cell count was 512 cells/ml
(SD=115). The baseline characteristics for the participants
randomized to the experimental and c-ART arms were similar
(CD4
+ T cell count: 259 and 282 cells/ml , respectively; p=0.15.
log10 Viral load: 4.65 and 4.69, respectively; p.0.5); one subject
(arm 2) was lost to follow-up.
Effect of ART interruptions on HIV viral load
HIV viral load was monitored at each visit (Fig. 2); as expected,
participants in the c- ART predominantly maintained undetect-
able (,400 copies/ml) HIV viral load throughout the post-
randomization period. Treatment interruptions resulted in viral
load elevation: 60% (10 of 25) of Arm 1 participants had
detectable viral load during the 2-week ART interruption, 91.3%
(22 of 24) during the 4-week interruption and 95% (21 of 22)
during the 8-week interruption. At week 72 of post-randomization
follow up, all subjects in arm 2 and 24 of 27 subjects in arm 1 had
undetectable viral load. All study participants had undetectable
HIV viral load at the end of the post-trial follow-up.
Primary study outcomes
Our primary outcome was frequency of CD4
+ T cell count
measurements .350 cells/ml (CD4 success) over multiple
measurements in the 72-week period following randomization.
As illustrated in Fig. 3, the majority of observed CD4
+ T cell count
measurements were above 350 cells/ml throughout the random-
ized period of the study (week 24–96) with an overall 6% of
measurements (27/453) dropping below 350 cells/ml; the propor-
tion of ,350 cells/ml CD4
+ T cell count measurements for was
22/261 (8.4%) for arm 1 and 5/192 (2.6%) for arm 2.
Figure 3. Primary study outcome. The box plot represents the
percent of successful outcomes (CD4
+ T cell count .350 cells/ml)over all
post-randomization visits in the two study arms; boxes represent 5
th,
25
th,5 0
th (median), 75
th and 95
th percentiles. Outliers are represented
as individual circles.
doi:10.1371/journal.pone.0021450.g003
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endpoint analysis as listed in Table 1, the mean proportion of
CD4
+ T cell counts above 350 cells/ml was 82.12% (SD=24.47)
for arm 1 and 93.75 (SD=17.77) for arm 2. The difference
between arms in this primary endpoint was 11.6% (upper limit of
97.5% CI, 24.1%) which exceeded the threshold for non-
inferiority. A two-sided 95% CI for the difference in means
between arms is (20.16, 23.4). The same conclusion is reached
based on observed (non-imputed) data (mean values 91.85% for
arm 1 and 97.6% for arm 2; confidence interval limit .10%; two-
sided 95% CI: 1.47, 10.04).
Few clinical events occurred with only one opportunistic
infection in arm 1 (pulmonary TB) and none in arm 2. Two
participants developed serious illnesses (pneumonia and transient
ischemic attack symptoms) after randomization thereby contrib-
uting to imputed outcomes although occurring before the
initiation of any scheduled interruptions. Three other patients in
arm 1 were withdrawn due to virological failure at week 16.
However, there was no evidence of HIV-1 genotypic drug
resistance and upon further adherence counselling off study,
HIV viral loads became undetectable in all ‘‘failed’’ subjects.
There were 2 clinical diagnoses of lipodystrophy in each arm.
Post-randomization, one participant was lost to follow up in arm 2
with no losses to follow-up in arm 1. Two participants in arm 2
were terminated from the study due to withdrawals of consents.
No deaths were recorded after randomization.
Secondary study outcomes
Effects of intermittent ART on CD4
+ T cell count
levels. Fig. 4 illustrates the CD4
+ T cell count value per study
subject for each study week, including those on and off ART for
the experimental group. Week 22 (week 0 of randomization)
represents the CD4
+ T cell count distribution of the participants
before randomization. Using a mixed-effect model, we estimated
the slope of change in CD4
+ T cell count over the entire study
period (Fig. 5). The effect of time (estimate=1.6 CD4+ T cells/ml/
day; p,0.0001), was significantly affected by arm assignment (est.
for interaction=21.54; p=0.003), indicating that arm 2 had a 1.6
cells/ml /week increase, whereas arm 1 had a 0.1 cells/ml /week
change.
Baseline CD4
+ T cell count had no detectable effect on the
CD4
+ T cell count levels measured at the end any of the
interruptions (2, 4 or 8 weeks, p=0.13; .0.5 and 0.40
respectively), as assessed in arm 1 using linear modelling. Similarly,
baseline HIV viral load was also not found to predictive of off-
ART viral replication (Viral Load at STI end).
Effects of intermittent ART on treatment adherence. Pill
count-based adherence assessment indicated that adherence was
high for all individuals for each of the three study drugs (Fig. 6).
Values were 99.2% (arm 1) and 98.1% (arm 2) for stavudine,
99.2% (arm 1) and 98.1% (arm 2) for stavudine/zidovudine fixed
dose combination and 99.2% (arm 1) and 98.2% (arm 2) for
Ritonavir/Lopinavir. Adherence was highly correlated between
Figure 4. CD4 counts over the study period. The graphic represents individual CD4
+ T cell counts at each study visit. Crosses=cART;
circles=intermittent ART; the continuous line represent the CD4
+ T cell count cutoff for failure (350 cells/ml).
doi:10.1371/journal.pone.0021450.g004
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There was no evidence that the intervention had an effect on
adherence while subjects were on ART.
Resistance testing. Samples from individuals in the
intermittent arm after the last 8 week interruption were tested
for evidence of genotypic resistance mutations by population
sequencing. From these 24 samples, 23 reverse transcriptase (RT)
and 21 protease sequences were generated. One sample had the
NNRTI mutation K103N which was also present in a sample
collected from the same patient 6 months previously. None of the
other samples had RT resistance mutations. Another sample had
the M46I mutation in the protease gene which decreases
susceptibility to some PIs when present with other mutations.
None of the other 20 samples had PI mutations. Only sequences
from the same patient clustered together but all clustered with
HIV-1 subtype C sequences.
Discussion
We present the results of an STI study using sequential
scheduled short cyclic interruption utilizing a PI-based regimen in
ART naive patient with CD4
+ T cell count nadir .200 cells/ml,
CD4
+ T cell count .450 cells/ml on therapy, and no history of OI
in a resource limited setting.
According to our conservative definition of non-inferiority,
which imputed treatment related adverse events as CD4 failures
(see Table 1), our results do not support the hypothesis that an
intermittent ART regimen is not inferior to intermittent ART.
Interestingly, there was no significant excess of OI or AIDS-
defining illness in arm 1 which occurred in other studies [4,7,8,21].
The selection of patients with CD4
+ T cell count nadirs .200
cells/ml and without previous history of OI or AIDs defining
illnesses may have contributed to the absence of clinical events in
the intermittent ART arm.
Our modelling analysis indicates that the trajectory of CD4
+ T
cell count rise over time is significantly different for subjects
undergoing intermittent ART. As we did not evidence any actual
loss of CD4
+ T cells, we conclude, expanding on prior studies
[16,22], that the immunological cost of interrupting ART may be
the loss of CD4
+ T cell gains observed with continuous ART,
rather than a decrease below pre-randomization levels.
Unlike previously reported NNRTI-based ART STI studies
[10,11,21,23], we did not observe evidence of genotypic resistance
to ART in arm 1, possibly in relation to the use of ritonavir/
lopinavir-based regimen. Despite the use of lamivudine, M184V
resistance mutation (commonly observed in STI studies) was not
found here; the K103N mutation found in one individual may be
the result of exposure to ARV at an earlier time, possibly
Figure 5. Effect of intermittent ART on CD4 count over time: mixed effect modeling. The effect of time and ARM assignment on CD4+ T
cell count was assessed using a Mixed Effect linear model (MEM) as detailed in the text. the continuous lines represent the CD4
+ T cell count
predicted by the application of the model. Crosses=cART; circles=intermittent ART; dashed line: effect of time and assignment to cART arm; solid
line: effect of time and assignment to intermittent ART arm.
doi:10.1371/journal.pone.0021450.g005
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transmission [20], or transmitted drug-resistance. It is not clear
if the M46I mutation that was found in one patient was selected by
the current regimen as this mutation also occurs at low frequency
in drug-naive individuals [24]; analysis of pre-ART samples would
be necessary to determine if this was a naturally occurring
polymorphism. The three patients that failed to re-suppress within
12 weeks after ART resumption had no detectable resistance
mutations; these subjects achieved viral suppression after adher-
ence counselling without ART regimen changes: thus, the lack of
suppression appeared to be due to temporal non-adherence.
Adherence was very high in both arms (consistent with previous
studies [2]) and was not significantly affected by treatment
interruptions; the 24 weeks on ART before randomized may
have further selected the patients with high treatment adherence,
as non-adherent patients would have experienced virological
failure leading to study termination before randomization [25,26].
This study had some limitations. First, sample size was limited,
making it difficult to compare our clinical outcome data against those
of larger studies (e.g. SMART). Second, by incorporating safety
endpoints (imputed as primary outcomes counted as loss of CD4
+ T
cells even if observed CD4
+ Tc e l lc o u n t.350 cells/ml), our non-
inferiority definition conservatively favoured the continuous ART
arm: we justify this approach under the premise that any adverse
clinical outcome associated with this strategy should be reflected in
primary end-point. Finally, we note that the observed sample
standard deviation is much larger than the standard deviation (7.07)
assumed for the initial sample size calculations. If indeed, the
standard deviation were 18, then this study was powered to detect
non-inferiority defined as a difference (in the mean percentage of
CD4 counts .350 between groups) of less than 20%. Our conclusion
that the results do not support non-inferiority remains appropriate.
While the results from the present and other studies conducted in
resource-constrained countries overall do not support intermittent
ART as a routine treatment strategy, treatment interruptions
remain a reality of medical care in this environment, due to
discontinuity in supply chains and healthcare delivery [27],
displacement [28], and individual behavioural [29] and economic
Figure 6. Treatment adherence. Adherence to individual ART regimen components (indicated) was calculated as specified in the text, and is
represented in the form of adherence rate class distribution (from 0.93 to 1%) for the cART arm (top panels) and the intermittent ART arm (bottom
panels). The contribution of the 3 individuals that failed to re-suppress to HIV RNA,50 copies/ml within 12 weeks from ART resumption is indicated
as filled stacked bars.
doi:10.1371/journal.pone.0021450.g006
ART Interruptions in South Africa
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e21450[30,31,32] adherence issues leading to treatment discontinuations
and/or modifications [33]. Our data suggest that a PI-based
regimen may be less likely to result in clinical failure than NNRTI-
based regimens if ART interruptions occur; however, the cost of
such interruptions, even in the absence of acquired genotypic
resistance to the PI-based regimen or development of OI and AIDS
defining illnesses, may be the forfeiture of the long-term gain in
CD4
+ T cell count that would be expected under continuous ART.
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